Related Experiment Video
Updated: Jul 4, 2026

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations
Published on: November 7, 2019
[Hemolytic uremic syndrome following gemcitabine treatment]
V Bourquin1, A Guinand, C Haenni
1Service de Néphrologie, HUG, 1211 Genève 14. vincent.bourquin@hcuge.ch
Abstract:
Hemolytic uremic syndrome (HUS) in children is classically associated with diarrheas related to the production of a shiga-toxin. HUS occurs among oncologic patients, in relation with the cancer itself, or as a complication of the cytostatic treatment. The physician should be familiar with the triad of HUS (microangiopathic hemolytic anemia, thrombocytopenia and renal failure) and search actively for this pathology in oncologic patient. The treatment is essentially empirical. It includes plasma exchanges, control of blood pressure, hydro-electrolytic balance control with dialysis, if necessary. Blood transfusion should be avoided. Potential mortal complications associated with HUS can be prevented by a rapid diagnosis and a prompt initiation of adequate therapy.
Related Concept Videos
Hemodialysis II: Procedure and Complications
Hypersensitivity Reactions: Cytolytic Reactions
Nephrotic Syndrome I : Introduction
Kidney Transplant II: Surgical Procedure
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Cytotoxic Edema: Pathophysiology